Newron Pharmaceuticals S.p.A. (NWRN.SW)

CHF 8.0

(11.73%)

Total Liabilities Summary of Newron Pharmaceuticals S.p.A.

Newron Pharmaceuticals S.p.A.'s latest annual total liabilities in 2023 was 55.77 Million EUR , up 8.88% from previous year.
Newron Pharmaceuticals S.p.A.'s latest quarterly total liabilities in 2024 Q2 was 55.76 Million EUR , down 0.0% from previous quarter.
Newron Pharmaceuticals S.p.A. reported annual total liabilities of 51.22 Million EUR in 2022, up 8.12% from previous year.
Newron Pharmaceuticals S.p.A. reported annual total liabilities of 47.37 Million EUR in 2021, up 39.55% from previous year.
Newron Pharmaceuticals S.p.A. reported quarterly total liabilities of 52.45 Million EUR for 2023 Q2, down 0.0% from previous quarter.
Newron Pharmaceuticals S.p.A. reported quarterly total liabilities of 55.77 Million EUR for 2023 FY, up 8.88% from previous quarter.

Annual Total Liabilities Chart of Newron Pharmaceuticals S.p.A. (2023 - 2005)

Historical Annual Total Liabilities of Newron Pharmaceuticals S.p.A. (2023 - 2005)

Year	Total Liabilities	Total Liabilities Growth
2023	55.77 Million EUR	8.88%
2022	51.22 Million EUR	8.12%
2021	47.37 Million EUR	39.55%
2020	33.95 Million EUR	44.54%
2019	23.49 Million EUR	354.97%
2018	5.16 Million EUR	-2.64%
2017	5.3 Million EUR	-22.52%
2016	6.84 Million EUR	-5.83%
2015	7.26 Million EUR	-6.98%
2014	7.81 Million EUR	-25.79%
2013	10.52 Million EUR	-38.21%
2012	17.03 Million EUR	144.08%
2011	6.98 Million EUR	0.58%
2010	6.94 Million EUR	-44.0%
2009	12.39 Million EUR	-15.85%
2008	14.72 Million EUR	13.58%
2007	12.96 Million EUR	-29.13%
2006	18.29 Million EUR	182.52%
2005	6.47 Million EUR	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q2	55.76 Million EUR	0.0%
2023 Q2	52.45 Million EUR	0.0%
2023 FY	55.77 Million EUR	8.88%
2023 Q4	55.77 Million EUR	0.0%
2022 Q2	48.78 Million EUR	0.0%
2022 FY	51.22 Million EUR	8.12%
2022 Q4	51.22 Million EUR	0.0%
2021 FY	47.37 Million EUR	39.55%
2021 Q4	47.37 Million EUR	0.0%
2021 Q2	31.19 Million EUR	0.0%
2020 Q4	33.95 Million EUR	0.0%
2020 FY	33.95 Million EUR	44.54%
2020 Q2	30.71 Million EUR	0.0%
2019 Q2	17.85 Million EUR	0.0%
2019 Q4	23.49 Million EUR	0.0%
2019 FY	23.49 Million EUR	354.97%
2018 Q4	5.16 Million EUR	0.0%
2018 FY	5.16 Million EUR	-2.64%
2018 Q2	4.08 Million EUR	0.0%
2017 Q2	4.84 Million EUR	0.0%
2017 FY	5.3 Million EUR	-22.52%
2017 Q4	5.3 Million EUR	0.0%
2016 Q2	6.33 Million EUR	0.0%
2016 Q4	6.84 Million EUR	0.0%
2016 FY	6.84 Million EUR	-5.83%
2015 Q4	7.26 Million EUR	0.0%
2015 FY	7.26 Million EUR	-6.98%
2015 Q2	8.56 Million EUR	0.0%
2014 Q2	10.22 Million EUR	0.0%
2014 FY	7.81 Million EUR	-25.79%
2014 Q4	7.81 Million EUR	0.0%
2013 Q4	10.52 Million EUR	0.0%
2013 Q2	11.61 Million EUR	0.0%
2013 FY	10.52 Million EUR	-38.21%
2012 Q2	14.9 Million EUR	0.0%
2012 Q4	17.03 Million EUR	0.0%
2012 FY	17.03 Million EUR	144.08%
2011 Q2	7.33 Million EUR	0.0%
2011 FY	6.98 Million EUR	0.58%
2011 Q4	6.98 Million EUR	0.0%
2010 Q2	11.72 Million EUR	0.0%
2010 FY	6.94 Million EUR	-44.0%
2010 Q4	6.94 Million EUR	0.0%
2009 Q4	12.39 Million EUR	0.0%
2009 FY	12.39 Million EUR	-15.85%
2008 FY	14.72 Million EUR	13.58%
2007 FY	12.96 Million EUR	-29.13%
2006 FY	18.29 Million EUR	182.52%
2005 FY	6.47 Million EUR	0.0%

Peer Total Liabilities Comparison of Newron Pharmaceuticals S.p.A.

Name	Total Liabilities	Total Liabilities Difference
Addex Therapeutics Ltd	3.49 Million CHF	-1495.174%
BB Biotech AG	304.9 Million CHF	81.707%
Basilea Pharmaceutica AG	183.29 Million CHF	69.571%
Evolva Holding SA	4.27 Million CHF	-1204.472%
Idorsia Ltd	1.46 Billion CHF	96.203%
Kuros Biosciences AG	19.19 Million CHF	-190.58%
Molecular Partners AG	21.92 Million CHF	-154.409%
Relief Therapeutics Holding AG	24.16 Million CHF	-130.834%
Santhera Pharmaceuticals Holding AG	49.68 Million CHF	-12.253%